Here’s what you should know.
1. The company expects results in the second quarter of fiscal year 2017.
2. Researchers conducted a randomized, double-blind, placebo-controlled study of Bekinda in patients with acute gastroenteritis and gastritis.
3. If the FDA approves Bekinda, it would be the first 5-HT3 antiemtetic drug designed for acute gastroenteritis and gastritis available in the United States.
4. RedHill is conducting a phase II study for its 12 mg version. The lower dose can treat diarrhea-predominant irritable bowel syndrome. RedHill expects to report results in mid-2017.
More articles on gastroenterology:
Takeda completes Ariad Pharmaceutical acquisition following NY law firm investigation — 3 GI companies making waves
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
